Amphastar Pharmaceuticals, Inc. (AMPH): Gross Profit
$356.06M
Year ended 2025-12-31
$348.11M
Trailing 12 months to 2026-06-30
+12.7%
3-year compound annual growth
+20.0%
5-year compound annual growth
+16.5%
10-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $356.06M | -4.8% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $373.86M | +6.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $351.12M | +41.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $248.86M | +24.6% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $199.74M | +39.3% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $143.34M | +8.7% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $131.92M | +23.3% | 2022-03-11, From 2019-01-01 |
| 2018-12-31 | $106.98M | +18.2% | 2021-03-15, From 2018-01-01 |
| 2017-12-31 | $90.51M | -13.1% | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | $104.20M | +34.7% | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $77.35M | +50.9% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $51.26M | -41.1% | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | $86.96M | -3.7% | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | $90.30M | n/a | 2015-03-26, From 2012-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $356.06M | -4.8% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $644.39M | +10.4% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $576.66M | +8.7% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $416.70M | +15.0% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $599.89M | +65.6% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $463.26M | +22.8% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $515.57M | +77.5% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $205.94M | -5.8% |
| Insmed Inc (INSM) | 2025-12-31 | $483.49M | +73.9% |
Compare AMPH, SUPN, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗